Top Medical Searches

Actelion, being bought by J&J, says full year core net income rose 27 percent

The company's logo is seen at the headquarters of Swiss biotech company Actelion in AllschwilSwiss drugmaker Actelion's 2016 core net income rose 27 percent on accelerating sales of its newer medicines to treat deadly pulmonary arterial hypertension (PAH), it said on Tuesday. Core net income rose to 881 million Swiss francs ($877.8 million) from 693 million francs in the previous year, the company said in a statement. Sales rose 18 percent to 2.42 billion francs, in line with the 2.41 billion francs expected in a Reuters poll.

Read More..

Be Sociable, Share!
February 14th, 2017 Posted in Drug
Copyright 2008 © Drugs and Diseases. Developed by Axilosoft
Home | About Us | Privacy Policy | Contact Us